Skip to content

Incyte INCY Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$327K+61.9%
Gilead Sciences logo
Gilead SciencesGILD
-$4.24B-23.7%
Geron logo
GeronGERN
$2.43M+847%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$23.37M+104%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+70.1%
Enterprise value$22.01B+64.9%
P/E16.1×-1.4×
P/S4.5×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's financing cash flow?
Incyte (INCY) reported financing cash flow of $65.46M in Q2 2026.
How has Incyte's financing cash flow changed year-over-year?
Incyte's financing cash flow increased by 682.0% year-over-year, from -$11.25M to $65.46M.
What is the long-term trend for Incyte's financing cash flow?
Over 4 years (2021 to 2025), Incyte's financing cash flow has grown at a 101.1% compound annual growth rate (CAGR), from $6.18M to $101.04M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.